Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

Martin Kropff; Stefan Goranov; et al.

$Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial$

Б 335

Детайли

Източник

Haematologica

Местоиздаване

Pavia

Година на издаване

2012

Пор.№

Страници

784-791

Класификационен индекс

УДК	Значение
616.71-018.46-006.448	Миелома

Том

Ключови думи

Автори от МУ - Пловдив

Допълнителна информация

ISSN: 0390-6078
Системен №: 31579
Тематични рубрики: Хематология

Действия

APA Chicago / Turabian (16th edition) Harvard MLA (7th edition)

Kropff, M., Goranov, S., al., e. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial, , 2012, 784-791.

Kropff, M., Goranov, S., al., e. . Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Pavia: , 2012, 784-791.

Kropff, M., Goranov, S., al., e. (2012) Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial, Pavia: , 784-791

Kropff, M., Goranov, S., & al., e. (2012). Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. Pavia: 97 (5), 784-791.